返回 Agenda
Session 5, Track A: Latest Advancements in AI – A Regulatory Perspective
Session Chair(s)
Louise Blythe, MSC
Head, Regulatory Affairs, Bayer Inc. Canada, Canada
Melanie Cote, MS
Senior Manager, Global Regulatory Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., Canada
In the rapidly evolving field of artificial intelligence (AI), regulatory professionals are encouraged to engage with ongoing developments in AI regulatory frameworks and explore how AI can be leveraged within their practices. This session will delve into the emerging AI regulatory framework and its implications for regulatory professionals. Through industry use cases, participants will gain insights into real-world AI experiences in Regulatory Affairs. The session will also address the benefits, challenges and risks associated with the implementation of AI.
Learning Objective : - Explore Health Canada's emerging artificial intelligence (AI) regulatory framework and its potential impact on regulatory processes
- Discuss industry use cases to illustrate the application of AI in Regulatory Affairs
- Recognize the benefits, challenges and risks related to the implementation of AI
Speaker(s)
Benny Ling, MSC
Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau, Health Canada, Canada
AI Initiatives – Use Cases
Sridevi Nagarajan, PHD
DIA Communities Chair for AI in Healthcare, Ayusarogya, United Kingdom
Demystifying AI in Healthcare
Carrie Ku, MSC
Head of Regulatory Affairs, sanofi-aventis Canada Inc, Canada
AI Initiatives – Use Cases